Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
International Journal of Hematology|December 13, 2025
Biomarker-driven strategies and challenges in acute graft-versus-host disease clinical trialsNikolaos Katsivelos, Ioannis E Louloudis, Nikolaos Spyrou, et al.
Transplantation and Cellular Therapy|December 6, 2025
Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR AnalysisYu Akahoshi, Nelli Bejanyan, Hideki Nakasone, et al.
British Journal of Haematology|March 3, 2020
Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemiaYu Akahoshi, Aiko Igarashi, Takahiro Fukuda, et al.
Transplantation and Cellular Therapy|July 1, 2026
Real-world use of maribavir for refractory CMV infection and intolerance to conventional anti-CMV agents after allogeneic hematopoietic cell transplantationRisa Nishiyama, Ayumu Ito, Yu Akahoshi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 17, 2018
Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor EraYu Akahoshi, Shuichi Mizuta, Hiroaki Shimizu, et al.
Bone Marrow Transplantation|May 25, 2020
Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCTYu Akahoshi, Satoshi Nishiwaki, Yasuyuki Arai, et al.
International Journal of Hematology|February 11, 2021
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemiaYu Akahoshi, Yasuyuki Arai, Satoshi Nishiwaki, et al.
Blood Advances|November 8, 2019
Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCTYu Akahoshi, Hideki Nakasone, Koji Kawamura, et al.
Experimental Hematology|January 14, 2020
Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib eraYu Akahoshi, Hideki Nakasone, Koji Kawamura, et al.
Annals of Hematology|March 17, 2020
Impact of blood pressure early after allogeneic hematopoietic cell transplantation on clinical outcomesMasaharu Tamaki, Hideki Nakasone, Shunto Kawamura, et al.
Pageof 11